FDA Inspection 998358 — Xinjiang Nuziline Biopharmaceutical Co., Ltd.
The FDA completed an inspection of Xinjiang Nuziline Biopharmaceutical Co., Ltd. on Nov 11, 2016 in Xinjiang. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Nov 11, 2016
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Xinjiang (China)